ArticleFrontiers in public health2026
Longitudinal studies on financial toxicity in cancer patients: a scoping review.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This scoping review focuses on financial toxicity in cancer patients, aiming to identify its measurement time points, assessment tools, developmental trends, and influencing factors. Based on existing evidence, this review reveals the occurrence trajectory and long-term impacts of financial toxicity among cancer patients. It can provide a reference for improving patients' financial well-being in clinical practice and optimizing the medical security system at the health policy level and also points out key directions for future related research. Methods: This study strictly followed the methodology of scoping review. A systematic search was performed across the databases including PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wan Fang Data, VIP, and Chinese Biomedical Literature Database (CBM). The search period covered from the inception of each database to November 8, 2025. Results: A total of 14 articles were included in this study. The common measurement time points were selected as before the initiation of treatment, 3 months, 6 months, and 12 months after the start of treatment. The research tools combined subjective scales with objective data measurement, and the Comprehensive Score for Financial Toxicity-Patient-Reported Outcome Measure (COST-PROM) was adopted in most studies. The changing trend of financial toxicity among breast cancer patients tended to be stable. The financial toxicity of colorectal cancer patients showed a continuous upward trend, while that of esophageal cancer patients presented a continuous downward trend. The financial toxicity of cervical cancer patients also demonstrated a declining trend, though the magnitude of change was smaller than that of esophageal cancer patients. A total of 25 influencing factors of financial toxicity in cancer patients were identified, involving four dimensions: sociodemographic factors (4), disease-related factors (4), economic-related factors (11), and psychosocial factors (6). Conclusion: The measurement time points of financial toxicity in cancer patients are mostly concentrated within one year after treatment, with insufficient research on long-term follow-up. The existing assessment tools lack applicability for long-term tracking and specificity for different cancer types, and objective indicators fail to effectively reflect patients' economic status due to disparities in regional economic development levels. Patients with different types of cancer exhibit distinct developmental trends of financial toxicity, indicating population heterogeneity. Future research still needs to further explore the influencing factors and developmental trajectories of financial toxicity among different cancer types.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.